Holen Sie sich die Stockscreener-App
123.02
7.67%
-10.22
Vorhandelsmarkt:
127.75
4.73
+3.84%
Schlusskurs vom Vortag:
$133.24
Offen:
$135
24-Stunden-Volumen:
183.13K
Relative Volume:
0.41
Marktkapitalisierung:
$69.27M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-130.87
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
-16.97%
1M Leistung:
+1,487%
6M Leistung:
-86.69%
1J Leistung:
-90.34%
1-Tages-Spanne:
$112.95
$138.45
1-Wochen-Bereich:
$112.95
$148.88
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Vergleichen Sie SPRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
123.02 | 75.08M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - healthcare-brew.com
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus
Spruce Biosciences stock price target raised to $160 from $10 at Leerink - Investing.com Philippines
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Mintz Advises the Placement Agents in Spruce Biosciences, Inc.’s $50 Million Private Placement - Mintz
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In - ts2.tech
Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research - Defense World
SPRUCE BIOSCIENCES, INC. trading resumes - MSN
SPRB director steps down; company notes no disagreement - Stock Titan
Spruce Biosciences, Inc. Announces Resignation of Bali Muralidhar as Member of Board of Directors and as Member of the Compensation Committee of the Board, Effective October 15, 2025 - MarketScreener
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Head to Head Contrast: PyroGenesis Canada (NASDAQ:PYRGF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - sharewise.com
Spruce Biosciences’ (SPRB) “Sell (D-)” Rating Reaffirmed at Weiss Ratings - Defense World
Spruce Biosciences insider filing shows 256-share buy, 1,050 held - Stock Titan
Spruce Biosciences to sell 502,181 shares at $68.00 in private placement - MSN
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1% – What’s Next? - Defense World
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1%What's Next? - MarketBeat
Medical Stocks To ConsiderOctober 6th - MarketBeat
Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 By Investing.com - Investing.com UK
Spruce Biosciences, Inc. announced that it has received $49.999769 million in funding - MarketScreener
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 - Investing.com India
SPRUCE BIOSCIENCES, INC. trading halted, volatility trading pause - MSN
Spruce Biosciences announces $50M private placement financing - TipRanks
Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus
Three Biotech Stocks Jump After Big Regulatory Wins - Finimize
Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Th - GuruFocus
Spruce Biosciences to Raise $50 Million Through Private Placement; Shares Down Pre-Bell - MarketScreener
Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus
Spruce Biosciences secures $50 million in private placement By Investing.com - Investing.com Canada
Spruce Biosciences secures $50 million in private placement - Investing.com
Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - MSN
Spruce Biosciences announces $50.0 million private placement financing - MarketScreener
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
Small Cap Stocks To Follow Today – October 6th - Defense World
Understanding the Current Trends in SPRB Stock - Info Petite Nation
Medical Stocks To Consider – October 6th - Defense World
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com
SPRB Stock Hits 19-Month High Amid Trading Halts - NewsBreak: Local News & Alerts
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
Spruce Biosciences Soars: What’s Driving the Surge? - timothysykes.com
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why - NewsBreak: Local News & Alerts
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):